Board of Directors
Bruce Downey, J.D. has served as a member of our Board of Directors since December 2015 and, since June 2022, has served as Chairman of our Board of Directors. Previously, Bruce was Chairman and Chief Executive Officer of Barr Pharmaceuticals, a global generic pharmaceutical manufacturer, until its acquisition by Teva Pharmaceuticals in 2008. He has served on a part-time basis as an Advisory Partner of NewSpring Health Capital II, L.P., a venture capital firm, since April 2009. Prior to Barr Pharmaceuticals, Bruce was a practicing attorney for 20 years, working in both the private sector and for the federal government, including the U.S. Department of Justice and the U.S. Department of Energy. In addition, he serves on the boards of directors of OncoPep, a biotechnology company, and Cardinal Health, a healthcare services company, since April 2011 and July 2009, respectively. Bruce previously served on the boards of directors of Melinta Therapeutics, a biopharmaceutical firm, and Momenta Pharmaceuticals, a biotechnology company acquired by Johnson & Johnson. He holds a J.D. from Ohio State University and a B.S. in economics from Miami University.
Ken Anderson, M.D. is a co-founder and has served as a member of our Board since December 2015. Dr. Anderson has also served as the Kraft Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr. Anderson serves on the following boards of directors: Window Therapeutics, a biotechnology company developing therapies that advance treatment options for patients with cancer and other serious diseases, since January 2021; Dynamic Cell Therapies, Inc. (formerly Raqia Therapeutics, Inc.), a CAR-T cell therapies company for cancer and other diseases, since September 2020; and Starton Therapeutics, Inc., a biotechnology company focused on blood cancer treatments, since September 2020. Dr. Anderson holds an M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.
Laura Bessen, M.D., has served as a member of our Board of Directors since August 2022. Dr. Bessen currently serves as managing partner at Maxsam Advisors where she provides strategic clinical and medical affairs advice to clients across the biotechnology and pharmaceutical industries. Previously, she held roles of increasing responsibility over a 15-year career at Bristol Myers Squibb (BMS), most recently as Vice President, Head of US Medical. During her tenure at BMS, she helped launch 11 new products including Opdivo®, Yervoy®, Empliciti®, and Eliquis® and co-led BMS’ partnership with Gilead to develop Atripla®. Dr. Bessen also co-led the development of a BMS product commercialization model, life cycle management and launch investment principles. Earlier in her career, Dr. Bessen served in medical affairs roles at DuPont Pharmaceuticals. She currently serves on the board of directors of Artiva Biotherapeutics, an oncology company developing and advancing off-the-shelf, allogeneic natural killer cell therapies for patients with hematologic cancers or solid tumors, a role she has held since March 2022. Dr. Bessen received her M.D. degree from New York University School of Medicine and a B.S. in biochemistry from the State University of New York at Binghamton.
Glenn Dubin has served as a member of our Board of Directors since March 2021. Glenn is the Principal of Dubin & Co., a private investment company based in New York. Since 2012, Glenn has been a member of the board of directors and lead shareholder of Castleton Commodities International LLC, a global merchant energy company active in the physical and financial commodity markets and infrastructure investing. Glenn co-founded Highbridge Capital Management, an alternative asset management company that was acquired by J.P. Morgan Asset Management. Additionally, Glenn is active in a variety of philanthropic endeavors, including roles as founder and former Board chair of the Robin Hood Foundation, an organization that applies investment principles to charitable giving, the Mount Sinai Medical Center, where he and his wife, Dr. Eva Andersson-Dubin, established the Dubin Breast Center, a leading institution for breast cancer research and clinical care, and the Museum of Modern Art, where he is a member of the board of trustees.
Donna Grogan, M.D., has served as a member of our Board of Directors since August 2022. Dr. Grogan currently serves as Principal of Grogan Consulting where she supports clients across drug development, regulatory strategy, trial design and data interpretation. Between September 2013 and June 2019, Dr. Grogan served as Chief Medical Officer of Clementia Pharmaceuticals, which was acquired by Ipsen in April 2019. She previously served as Chief Medical Officer for several HealthCare Ventures portfolio companies including Anexon, Apofore and DecImmune. Between February 2007 and August 2011, Dr. Grogan served as Chief Medical Officer, Senior Vice President Clinical Development at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Earlier in her career, she held roles of increasing responsibility at Sepracor Inc. where she was involved in multiple high-profile product approvals including Lunesta®, Xopenex HFA® and Brovana®. Dr. Grogan previously served as a board member, including membership on the Compensation Committee and the Scientific Committee, of Momenta Pharmaceuticals until it was acquired by Johnson & Johnson in October 2020. She holds an M.D. from University of Illinois College of Medicine and a B.A. from the College of the Holy Cross.
Andrew Hirsch, MBA joined C4 Therapeutics in September 2020 and serves as our President, Chief Executive Officer, and a member of our Board of Directors. Previously, Andrew was Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals. Andrew has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector, including having previously served as President and Chief Executive Officer of BIND Therapeutics (BIND). Prior to being named President and Chief Executive Officer of C4 Therapeutics, Andrew held several other leadership positions at BIND, including Chief Operating Officer and Chief Financial Officer. Before joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics from June 2011 until its acquisition by Celgene. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen, including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. Since May 2017, Andrew has served on the Board of Directors of Editas Medicine. Andrew holds an MBA from the Tuck School at Dartmouth College and a B.A. in economics from the University of Pennsylvania.
Utpal Koppikar, MBA, has served as a member of our Board of Directors since March 2022. Utpal is currently the Chief Financial Officer of Verily, an Alphabet-backed company focused on precision health. Prior to joining Verily, he served as Executive Vice President and Chief Financial Officer at Atara Biotherapeutics from June 2018 to March 2022, where he oversaw the finance, information technology and investor relations functions and guided the company’s strategy as a member of its senior leadership team. Earlier in his career, Utpal held several senior financial leadership positions at Gilead Sciences (Gilead), including Vice President of Corporate and Operations Finance. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma and played a key role as Gilead’s Vice President of Finance Europe, Middle East and Australia in the launch of multiple HIV and HCV product launches. Before joining Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. Utpal previously served as a board member of Flexion Therapeutics Inc. until its sale to Pacira Biosciences in November 2021. He holds an MBA in finance from UCLA’s Anderson School of Management., an M.S. in aeronautical engineering from Stanford University and a B.S. in aerospace engineering from the University of Maryland.
Malcolm Salter has served as a member of our Board of Directors since December 2015. Malcolm is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. He currently serves on the following boards of directors: AI Proteins, a biotechnology company focused on the design and engineering of synthetic mini-protein therapeutics, since 2022; NextRNA, Inc., a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021; and Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020. From 1986 to 2006, he served as president of Mars & Co., a global strategy-consulting firm. He is a former Trustee of the Dana-Farber Cancer Institute. Mr. Salter holds an A.B., M.B.A., and a D.B.A. from Harvard University.
Marc Cohen was C4 Therapeutics’ visionary co-founder and Executive Chairman who passed away in June 2022. Throughout his life, Marc believed in “doing well by doing good,” which led him to invest in promising science that had the potential to help patients. He had a special talent for seeing the potential in revolutionary ideas before others, which we saw with the creation of C4T. He believed in the potential of targeted protein degradation science and was one of the first to see that it could become a new kind of medicine to fight cancer and other diseases. Marc’s vision was matched only by his endless energy to take these insights and harness them into medicines.
The numerous biotechnology companies he founded over the course of his career are a testament to his passion for using his gifts to help advance breakthrough science to treatments for patients. In addition to co-founding C4 Therapeutics in 2015, Marc also co-founded Regenacy Pharmaceuticals, where he served as Executive Chairman, NextRNA Therapeutics, where he also served as CEO and Executive Chairman and AI Proteins. He advanced therapeutic discoveries through his leadership at Frequency Therapeutics, Acetylon Pharmaceuticals, Mana Therapeutics, OncoPep and Dynamic Cell Therapies. He also served as Co-founder, Chairman and Chief Executive of Bublup, Inc., co-CEO, of Cobro Ventures, Inc., and co-founder and CEO of OPNET Technologies. Marc was also a long-time supporter and former trustee of the Dana-Farber Cancer Institute, where he co-founded the Dana-Farber Innovations Research Fund.